{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:36:03Z","timestamp":1793730963778,"version":"4.6.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013041","name":"Shiraz University of Medical Sciences Vice Chancellor of Research","doi-asserted-by":"publisher","award":["26886"],"award-info":[{"award-number":["26886"]}],"id":[{"id":"10.13039\/501100013041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bbrc.2025.153080","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:12:45Z","timestamp":1764720765000},"page":"153080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"795","author":[{"given":"Bahareh","family":"Hassani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-6706","authenticated-orcid":false,"given":"Amirsajad","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Tavakkoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Moosavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omidreza","family":"Firuzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbrc.2025.153080_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca - Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153080_bib2","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"Ca - Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bbrc.2025.153080_bib3","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/diagnostics11030562","article-title":"Pancreatic ductal adenocarcinoma: epidemiology and risk factors","volume":"11","author":"Ushio","year":"2021","journal-title":"Diagnostics"},{"issue":"8","key":"10.1016\/j.bbrc.2025.153080_bib4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"10242","key":"10.1016\/j.bbrc.2025.153080_bib5","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bbrc.2025.153080_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","article-title":"A new wave of innovations within the DNA damage response","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"4","key":"10.1016\/j.bbrc.2025.153080_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"30","key":"10.1016\/j.bbrc.2025.153080_bib8","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbrc.2025.153080_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ags3.12482","article-title":"Germline DNA damage repair gene mutations in pancreatic cancer patients with personal\/family histories of pancreas\/breast\/ovarian\/prostate cancer in a Japanese population","volume":"5","author":"Hata","year":"2021","journal-title":"Ann. Gastroenterol. Surg."},{"issue":"2","key":"10.1016\/j.bbrc.2025.153080_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbrc.2025.153080_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-07792-x","article-title":"Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma","volume":"21","author":"Xu","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bbrc.2025.153080_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cac2.12238","article-title":"Characterization of DNA damage response deficiency in pancreatic cancer patients from China","volume":"42","author":"Zhang","year":"2022","journal-title":"Cancer Commun."},{"issue":"6","key":"10.1016\/j.bbrc.2025.153080_bib13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2025.153080_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.610205","article-title":"Alkannin-induced oxidative DNA damage synergizes with PARP inhibition to cause cancer-specific cytotoxicity","volume":"11","author":"Chang","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bbrc.2025.153080_bib15","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/cancers12082098","article-title":"DNA damage-inducing anticancer therapies: from global to precision damage","volume":"12","author":"Reuvers","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.153080_bib16","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s10147-020-01721-x","article-title":"Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic\/breast\/ovarian\/prostate cancer or personal history of breast\/ovarian\/prostate cancer (FABRIC study)","volume":"25","author":"Okano","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.153080_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2019.10.023","article-title":"A multicenter, phase I\/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma\u2013TCOG T1211 study","volume":"124","author":"Chiang","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2025.153080_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211018539","article-title":"Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives","volume":"13","author":"Lellouche","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"6","key":"10.1016\/j.bbrc.2025.153080_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","article-title":"Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer","volume":"22","author":"Labrie","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"19","key":"10.1016\/j.bbrc.2025.153080_bib20","article-title":"Current molecular combination therapies used for the treatment of breast cancer","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bbrc.2025.153080_bib21","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1021\/acs.jmedchem.3c00322","article-title":"Discovery of ruthenium (II) metallocompound and olaparib synergy for cancer combination therapy","volume":"66","author":"Yusoh","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bbrc.2025.153080_bib22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1021\/acschembio.9b00843","article-title":"Metallointercalator [Ru (dppz) 2 (PIP)] 2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition","volume":"15","author":"Yusoh","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbrc.2025.153080_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241298329","article-title":"Update on combination strategies of PARP inhibitors","volume":"31","author":"Lin","year":"2024","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.bbrc.2025.153080_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41283-2","article-title":"Novel quinazoline-1, 2, 3-triazole hybrids with anticancer and MET kinase targeting properties","volume":"13","author":"Mortazavi","year":"2023","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.bbrc.2025.153080_bib25","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3390\/cancers14112640","article-title":"Pharmacologic induction of BRCAness in BRCA-proficient cancers: expanding PARP inhibitor use","volume":"14","author":"Abbotts","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.153080_bib26","article-title":"Introducing novel molecular-based method for quantification of homologous recombination efficiency","author":"Dibbasey","year":"2021","journal-title":"bioRxiv"},{"issue":"3","key":"10.1016\/j.bbrc.2025.153080_bib27","article-title":"A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers","volume":"5","author":"Alruwaili","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"4","key":"10.1016\/j.bbrc.2025.153080_bib28","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3390\/ijms22042056","article-title":"Effect of Oxaliplatin, Olaparib and LY294002 in combination on triple-negative breast cancer cells","volume":"22","author":"Andreidesz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153080_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.synres.2014.07.003","article-title":"Frequently asked questions in drug combinations and the mass-action law-based answers","volume":"1","author":"Chou","year":"2014","journal-title":"Synergy"},{"issue":"1","key":"10.1016\/j.bbrc.2025.153080_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13065-023-01073-3","article-title":"Synthesis and cytotoxic activity evaluation of novel imidazopyridine carbohydrazide derivatives","volume":"18","author":"Firouzi","year":"2024","journal-title":"BMC Chem."},{"issue":"12","key":"10.1016\/j.bbrc.2025.153080_bib31","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3109\/13880209.2014.908394","article-title":"Carthamus, Salvia and Stachys species protect neuronal cells against oxidative stress-induced apoptosis","volume":"52","year":"2014","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.bbrc.2025.153080_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.153080_bib33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bbrc.2025.153080_bib34","first-page":"2473","article-title":"Advances in heterocycles as DNA intercalating cancer drugs","volume":"8","author":"Das","year":"2023","journal-title":"Phys.Sci. Rev."},{"issue":"17","key":"10.1016\/j.bbrc.2025.153080_bib35","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.7150\/jca.47470","article-title":"Antibiotics for cancer treatment: a double-edged sword","volume":"11","author":"Gao","year":"2020","journal-title":"J. Cancer"},{"issue":"12","key":"10.1016\/j.bbrc.2025.153080_bib36","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/jpp\/rgac063","article-title":"Doxorubicin-induced cardiotoxicity: causative factors and possible interventions","volume":"74","author":"Jones","year":"2022","journal-title":"J. Pharm. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbrc.2025.153080_bib37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/cancers13040669","article-title":"Drug combination in cancer treatment\u2014From cocktails to conjugated combinations","volume":"13","author":"Gilad","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bbrc.2025.153080_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2025.153080_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2016.10.010","article-title":"PARP inhibitor combination therapy","volume":"108","author":"Drean","year":"2016","journal-title":"Crit. Rev. Oncol.-Hematol."},{"issue":"13","key":"10.1016\/j.bbrc.2025.153080_bib40","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.3390\/ijms22136825","article-title":"Gemcitabine-based chemoradiotherapy enhanced by a PARP inhibitor in pancreatic cancer cell lines","volume":"22","author":"Waissi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bbrc.2025.153080_bib41","doi-asserted-by":"crossref","first-page":"732","DOI":"10.15520\/jcmro.v3i11.362","article-title":"The treatment of clear cell ovarian cancer with the poly (ADP-ribose) polymerase (PARP1) inhibitors (AG14361, veliparib, olaparib) as chemosensitizers","volume":"3","author":"de Soto","year":"2020","journal-title":"J Current Med Res Opinion"},{"issue":"17","key":"10.1016\/j.bbrc.2025.153080_bib42","doi-asserted-by":"crossref","first-page":"15008","DOI":"10.18632\/oncotarget.3634","article-title":"PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting snail expression","volume":"6","author":"Mariano","year":"2015","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.bbrc.2025.153080_bib43","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1158\/1078-0432.CCR-13-3446","article-title":"Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus-resistant glioblastoma multiforme xenografts","volume":"20","author":"Gupta","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"null","key":"10.1016\/j.bbrc.2025.153080_bib44","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.2147\/OTT.S89154","article-title":"Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2\/M arrest and \u03b3-H2AX foci formation in colorectal cancer","volume":"8","author":"Xu","year":"2015","journal-title":"OncoTargets Ther."},{"issue":"6","key":"10.1016\/j.bbrc.2025.153080_bib45","first-page":"3223","article-title":"Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells","volume":"40","author":"Zhao","year":"2018","journal-title":"Oncol. Rep."},{"issue":"1\u20132","key":"10.1016\/j.bbrc.2025.153080_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2014.02.010","article-title":"Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer","volume":"348","author":"Chen","year":"2014","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.bbrc.2025.153080_bib47","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/ijc.31770","article-title":"PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non\u2010small\u2010cell lung cancer","volume":"144","author":"Jiang","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbrc.2025.153080_bib48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0006-2952(02)01508-3","article-title":"DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin","volume":"65","author":"Crul","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.153080_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2210-11-7","article-title":"Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells","volume":"11","author":"Alli","year":"2011","journal-title":"BMC Pharmacol."},{"issue":"21","key":"10.1016\/j.bbrc.2025.153080_bib50","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.bbrc.2025.153080_bib51","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","article-title":"PARP inhibitors: extending benefit beyond BRCA-Mutant cancers","volume":"25","author":"Pili\u00e9","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153080_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-13-95","article-title":"3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing","volume":"13","author":"Longati","year":"2013","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bbrc.2025.153080_bib53","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.trecan.2016.03.004","article-title":"Modeling pancreatic cancer with organoids","volume":"2","author":"Baker","year":"2016","journal-title":"Trends Cancer"},{"issue":"12","key":"10.1016\/j.bbrc.2025.153080_bib54","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3390\/pharmaceutics12121186","article-title":"Three-dimensional spheroids as in vitro preclinical models for cancer research","volume":"12","author":"Pinto","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2025.153080_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175395","article-title":"Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library","volume":"938","author":"Mortazavi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.153080_bib56","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1021\/acs.molpharmaceut.7b00843","article-title":"Ratio-dependent synergism of a doxorubicin and olaparib combination in 2D and spheroid models of ovarian cancer","volume":"15","author":"Eetezadi","year":"2018","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.bbrc.2025.153080_bib57","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/jphp.12539","article-title":"Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism","volume":"68","author":"Meredith","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.153080_bib58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1871520621666210608095512","article-title":"Reactive oxygen species (ROS): key components in cancer therapies","volume":"22","author":"Sahoo","year":"2022","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"4","key":"10.1016\/j.bbrc.2025.153080_bib59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin\u2014An agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.bbrc.2025.153080_bib60","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/med.21364","article-title":"Mitoxantrone, more than just another topoisomerase II poison","volume":"36","author":"Evison","year":"2016","journal-title":"Med. Res. Rev."},{"issue":"6","key":"10.1016\/j.bbrc.2025.153080_bib61","first-page":"2673","article-title":"Combination therapy of Doxorubicin with TTFields and radiation: newer approaches to combat lung cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbrc.2025.153080_bib62","first-page":"3741","article-title":"Apatinib-induced NF-\u03baB inactivation sensitizes triple-negative breast cancer cells to doxorubicin","volume":"12","author":"Tang","year":"2020","journal-title":"Am J. Transl. Res."},{"issue":"2","key":"10.1016\/j.bbrc.2025.153080_bib63","first-page":"2252","article-title":"Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met","volume":"15","author":"Shu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbrc.2025.153080_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101812","article-title":"Synergistic antitumor efficacy of rMV-Hu191 and Olaparib in pancreatic cancer by generating oxidative DNA damage and ROS-dependent apoptosis","volume":"39","author":"Zhang","year":"2024","journal-title":"Transl. Oncol."},{"issue":"21","key":"10.1016\/j.bbrc.2025.153080_bib65","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41388-018-0130-6","article-title":"PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53","volume":"37","author":"Liu","year":"2018","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bbrc.2025.153080_bib66","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/antiox12030667","article-title":"Auranofin synergizes with the PARP inhibitor olaparib to induce ROS-Mediated cell death in mutant p53 cancers","volume":"12","author":"Freire Boullosa","year":"2023","journal-title":"Antioxidants"},{"issue":"24","key":"10.1016\/j.bbrc.2025.153080_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246204","article-title":"Factors to consider for the correct use of \u03b3H2AX in the evaluation of DNA double-strand breaks damage caused by ionizing radiation","volume":"14","author":"Valente","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.bbrc.2025.153080_bib68","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1073\/pnas.1002175107","article-title":"A minority of foci or pan-nuclear apoptotic staining of \u03b3H2AX in the S phase after UV damage contain DNA double-strand breaks","volume":"107","author":"de Feraudy","year":"2010","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25017966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25017966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:03:13Z","timestamp":1781323393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25017966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":68,"alternative-id":["S0006291X25017966"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153080","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153080"}}